Phase II study of N‐methylformamide, spirogermanium, and 4‐demethoxydaunorubicin in the treatment of non‐small cell lung cancer (EST 3583): An Eastern cooperative oncology group study

David S. Ettinger, Dianne M. Finkelstein, Ross C. Donehower, Alex Y.C. Chang, Michael Green, Ronald Blum, Richard G. Hahn, John C. Ruckdeschel

Research output: Contribution to journalArticlepeer-review

Abstract

One hundred forty‐four patients with non‐small cell lung cancer, the majority (72%) of whom had received previous chemotherapy, were evaluable in this randomized phase II study of N‐methylformamide (N‐MF), spirogermanium, and 4‐demethoxydaunorubicin. There were two partial responses, one each with spirogermanium and 4‐demethoxydaunorubicin. There were eight life‐threatening complications (mostly hematologic) and two lethal complications (N‐MF, hematologic; 4‐demethoxydaunorubicin, gastrointestinal). The overall survival ranged from 9 days to 533 days with a median of 17.6 weeks. The following factors were associated with poor survival: Poor initial performance status, prior weight loss, presence of liver or subcutaneous metastases.

Original languageEnglish (US)
Pages (from-to)197-201
Number of pages5
JournalMedical and Pediatric Oncology
Volume17
Issue number3
DOIs
StatePublished - 1989

Keywords

  • advanced cancer
  • chemotherapy
  • investigational drugs

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of N‐methylformamide, spirogermanium, and 4‐demethoxydaunorubicin in the treatment of non‐small cell lung cancer (EST 3583): An Eastern cooperative oncology group study'. Together they form a unique fingerprint.

Cite this